logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
Y

Yan Xu

Chinese Academy of Medical Sciences
H指数:25
被引数:2,207

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Final analysis results from DREAMM-3, a phase 3 study of belantamab mafodotin versus pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

DREAMM-3研究的最终分析结果：belantamab mafodotin与pomalidomide联合dexamethasone治疗复发/难治性多发性骨髓瘤的III期研究

Blood Cancer Journal
IF11.6
2026-10-170
OAAI
Meletios Athanasios Dimopoulos; Vania Hungria; Haitao Meng; Atanas Radinoff; Jian Li; Sosana Delimpasi; Ting Niu; Gabor Mikala; Tamas Masszi; Marcelo Capra; Michael Low; Angelo Maiolino; Yan Xu; Xavier Leleu; Vasiliki Pappa; Dominik Chraniuk; Tatiana Konstantinova; Iurii Osipov; Shawn Hakim; Chris Brawley; Gabriela Tubel; Astrid McKeown; Julia Boyle; Sumita Roy-Ghanta; Katja Weisel
The Monoclonal Gammopathy of Undetermined Significance-Like (MGUS-like) Classifier Stratifies Prognosis in Multiple Myeloma: Results from Real-World Data in Chinese Population

Monoclonal Gammopathy of Undetermined Significance-Like (MGUS-like) 分类器在多发性骨髓瘤中分层预后：来自中国人群真实世界数据的结果

clinical lymphoma myeloma leukemia
IF0
2025-03-090
PRE
Wenqiang Yan; Jieqiong Zhou; Yuntong Liu; Jingyu Xu; Jian Cui; Chenxing Du; Shuaishuai Zhang; Rui Lv; Weiwei Sui; Shuhui Deng; Yan Xu; Shuhua Yi; Dehui Zou; Mu Hao; Lugui Qiu; Gang An
CAC-MM-001: A B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Followed By Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities

CAC-MM-001: 以B细胞成熟抗原（BCMA）为导向的嵌合抗原受体T细胞（CAR-T）疗法，随后进行自体干细胞移植和第二次CAR-T（CART-ASCT-CART2）治疗携带p53基因异常的新诊断多发性骨髓瘤患者

BLOOD
IF23.1
2024-11-050
PRE
Liu, Yuntong; Sui, Weiwei; Lyu, Rui; Du, Chenxing; Zhang, Shuaishuai; Yu, Tengteng; Xu, Jingyu; Yan, Wenqiang; Yan, Yuting; Liu, Wei; Wang, Yi; Wang, Qi; Xu, Yan; Yi, Shuhua; Zou, Dehui; Qiu, Lu-Gui; An, Gang
Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients

在超高风险多发性骨髓瘤（UHR-MM）患者中，托沃卡塔根自体白细胞（C-CAR088）联合自体干细胞移植（ASCT）显示出良好的安全性和有效性。

BLOOD
IF23.1
2024-11-050
PRE
Xu, Yan; Li, Wensi; An, Gang; Sui, Weiwei; Deng, Shuhui; Wang, Tingyu; Yi, Shuhua; Wang, Qi; Lyu, Rui; Xiong, Wenjie; Du, Chenxing; Liu, Wei; Huang, Wenyang; Zhu, Judy; Huang, Jiaqi; Zheng, Chengxiao; Lan, Liping; Zhu, Kevin; Oiu, Lugui; Zou, Dehui
Determination of MYD88 and CXCR4 Mutation for Clinical Detection and Their Significance in Waldenstrom Macroglobulinemia

MYD88和CXCR4突变在临床检测中的确定及其在华氏巨球蛋白血症中的意义

BLOOD
IF23.1
2024-11-050
PRE
Yu, Ying; Yan, Yuting; Xiong, Wenjie; Wang, Jun; Yao, Yao; Li, Yuxi; Wang, Tingyu; Lyu, Rui; Sun, Hao; Wang, Qi; Liu, Wei; An, Gang; Sui, Weiwei; Xu, Yan; Huang, Wenyang; Yu, Zhen; Zou, Dehui; Hao, Mu; Xiao, Zhi-jian; Wang, Jianxiang; Qiu, Lu-Gui; Yi, Shuhua
Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma

新诊断多发性骨髓瘤患者个体化加权骨髓瘤预后评分系统 (MPSS) 的开发和验证

AMERICAN JOURNAL OF HEMATOLOGY
IF9.9
2024-01-216
PRE
Mao, Xuehan; Yan, Wenqiang; Mery, David; Liu, Jiahui; Fan, Huishou; Xu, Jingyu; Xu, Yan; Sui, Weiwei; Deng, Shuhui; Zou, Dehui; Du, Chenxing; Yi, Shuhua; van Rhee, Frits; Barlogie, Bart; Shaughnessy Jr, John D.; Anderson, Kenneth C.; Zhan, Fenghuang; Qiu, Lugui; An, Gang
Longitudinal genetically detectable minimal residual disease by fluorescence in situ hybridization confers a poor prognosis in myeloma

通过荧光原位杂交纵向遗传可检测的最小残留疾病导致骨髓瘤预后不良

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
IF4.2
2024-01-191
OAAI
Cui, Jian; Yu, Tengteng; Lv, Rui; Liu, Jiahui; Fan, Huishou; Yan, Wenqiang; Xu, Jingyu; Du, Chenxing; Deng, Shuhui; Sui, Weiwei; Ho, Matthew; Xu, Yan; Anderson, Kenneth C.; Dong, Xifeng; Qiu, Lugui; An, Gang

研究方向

暂未获取到该数据
G
Gang An
H 指数:38论文数:789被引数:6,163
D
Dehui Zou
H 指数:29论文数:512被引数:3,144
S
Shuhua Yi
H 指数:25论文数:560被引数:2,024
S
Shuhui Deng
H 指数:21论文数:272被引数:1,469
W
Weiwei Sui
H 指数:21论文数:241被引数:1,352
L
Lugui Qiu
H 指数:43论文数:878被引数:8,515
郝
郝牧
H 指数:25论文数:335被引数:2,077
L
Lugui Qiu
H 指数:0论文数:7被引数:21
R
Rui Lv
H 指数:28论文数:191被引数:3,762
W
Wenqiang Yan
H 指数:7论文数:138被引数:152